FOSTER CITY, Calif. & YONGIN, South Korea--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and GC Pharma (KRX:006280) today announced that they have entered into an exclusive licensing ...
Mirum Pharmaceuticals Inc. plans to “move rapidly toward regulatory filings” to expand use of IBAT inhibitor Livmarli (maralixibat) into progressive familial intrahepatic cholestasis (PFIC), President ...
Mirum won two approvals from the U.S. Food and Drug Administration (FDA) last year. In February, the agency gave Ctexli a thumbs-up for the treatment of cerebrotendinous xanthomatosis (CTX), a rare ...
Although progressive familial intrahepatic cholestasis (PFIC) tends to draw more hoopla in the race, and Mirum Pharmaceuticals Inc. looks due to beat Albireo Pharma Inc. to market in Alagille syndrome ...
Mirum Pharmaceuticals is a biotech that markets therapies for underserved diseases. The company developed Livmarli, a treatment for severe itching in patients with Alagille syndrome, a rare condition ...
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), today announced the appointment of Joanne Quan, MD as Chief Medical Officer. Dr. Quan will lead the global clinical ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (“Mirum”) (Nasdaq: MIRM) today announced the pricing of its offering of $275.0 million aggregate principal amount of 4.00% convertible ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results